Amgen

Amgen will present new late-breaking Phase 3 clinical trial data as well as real-world evidence from our cardiovascular portfolio at the American Heart Association Scientific Sessions #AHA25. These data underscore the breadth of our cardiovascular research and latest insights as we work to advance cardiovascular care. 🔗 Learn more: https://lnkd.in/dUSDnjM9

Watch as the Amgen leadership team broke ground on the new center for science and innovation at our headquarters in Thousand Oaks, California. With construction now officially underway, this building is a symbol of the future of Amgen. It combines our excellence in R&D and Operations to scale innovation, accelerate discovery, and meet growing demand for breakthrough medicines. It’s where bold science meets real-world impact for every patient, every time. 🔗 Read more about this latest U.S. investment by Amgen, announced in September: https://amgen.ly/4nsptQx

After losing her father as a teen, Demetria began studying nursing to honor him but struggled to balance school and supporting her family. With limited career options, she felt lost—until Amgen’s apprenticeship program opened a new path. Today, she’s an Application Engineer in cybersecurity, building a meaningful career while helping others. Read her full story: https://bit.ly/4ny6X9n

Personal and professional development thrive at Amgen. From our apprenticeships and rotationals to a powerful culture of growth and support, this is a unique opportunity to fuel your career’s potential with a leading biotechnology company. Learn more: https://bit.ly/46tCS5x

The American College of Rheumatology Convergence is where new science, meaningful connections and opportunities to advance patient care come together. Our Amgen team is energized by the exchange of ideas and proud to share #ACR25 highlights – from research in uncontrolled gout and IgG4-RD to real-world effectiveness in ANCA-associated vasculitis.

This Breast Cancer Awareness Month, Amgen’s Emily Razaqi shares the story of her sister, Peggy, who passed away from breast cancer in August. “The tragedy for my sister was not how she passed away, because her passing was loving and peaceful, surrounded by everyone she cared about,” Emily shared. “The tragedy was that a 44-year-old ran out of options.” In conversation with Amgen colleague Michelle Carrillo, Emily honors her sister’s courage while living with multiple sclerosis and then facing a breast cancer diagnosis. “She told me, ‘Em, I literally will do anything to stay alive,’” Emily said. Watch the interview above to hear more from Emily about her sister Peggy.

We’ve officially entered the “Epithelial Era” of upper airway science. Research shows that in conditions like chronic rhinosinusitis with nasal polyps (#CRSwNP) and severe #asthma, symptoms typically begin with inflammation in the airway epithelium. At Amgen, we are committed to translating these scientific insights into meaningful progress for people living with chronic airway diseases. Hear from Narimon Honarpour, SVP, Global Development, about how these advances are reshaping our understanding of epithelial-driven inflammation and what that means for the future of care. 🔗 Dive deeper into the science behind epithelial-driven inflammation: https://amgen.ly/47kGGoM

Amgen is expanding its biotech innovation footprint in San Francisco with two floors of advanced R&D lab space designed to accelerate small molecule drug discovery. By bringing together medicinal chemists, computational and structural biologists, protein scientists, and bioassay experts, we’re fostering deeper collaboration to drive faster innovation. This investment reinforces our leadership in research and development and deepens our commitment to science that serves patients.

🔬 A new option for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) has been approved in the U.S. This milestone advances care for an often-overlooked condition and highlights the scientific shift toward recognizing #CRSwNP as an epithelial-driven disease, not just as a localized sinus condition. With this approval in CRSwNP, we are entering a pivotal new chapter in inflammatory research. Amgen remains committed to working with experts to raise awareness and support for people living with this condition. 🔗 Read more: https://lnkd.in/dArCrXjc

This week was more than events — it was about patients. 🫶At each Amgen site, #AmgenMissionWeek2025 showed how our mission comes to life, one inspiring moment at a time.